Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Low dose combination CDA substrate drug/cedazuridine with extended administration

Low dose combination CDA substrate drug/cedazuridine with extended administration

US Patent 11660310 · Granted May 30, 2023

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Combination decitabine and cedazuridine solid oral dosage forms2025
Combination decitabine and cedazuridine solid oral dosage forms2024
Low dose combination CDA substrate drug/cedazuridine with extended administratio2022
Low dose combination CDA substrate drug/cedazuridine with extended administratio2022
Low dose combination CDA substrate drug/cedazuridine with extended administratio2022
Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins2016
Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins2014
Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins2013
Photodynamic therapy of occult age-related macular degeneration2011
Method to prevent vision loss2006